Last reviewed · How we verify

NCT01703949

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Active, enrolled Phase 2 Last updated 11 June 2025
What this trial tests

Phase 2 trial testing Brentuximab Vedotin in Recurrent Hodgkin Lymphoma in 28 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 March 2013
Primary endpoint
3 June 2025
3 June 2030

Quick facts

Lead sponsorUniversity of Washington
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment28
Start date20 March 2013
Primary completion3 June 2025
Estimated completion3 June 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Washington

Who can join

18 and older, any sex, with Recurrent Hodgkin Lymphoma or Recurrent Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work better in treating patients with CD30+ lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.
    Chang HL, Schwettmann B, McArthur HL, Chan IS. · · 2023 · cited 72× · PMID 37712425 · DOI 10.1172/jci172156
  2. A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.
    Hermine O, Ramos JC, Tobinai K. · · 2018 · cited 61× · PMID 29411267 · DOI 10.1007/s12325-018-0658-4
  3. Novel Treatments of Adult T Cell Leukemia Lymphoma.
    El Hajj H, Tsukasaki K, Cheminant M, Bazarbachi A, et al · · 2020 · cited 34× · PMID 32547515 · DOI 10.3389/fmicb.2020.01062
  4. Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.
    Esnault C, Schrama D, Houben R, Guyétant S, et al · · 2022 · cited 19× · PMID 35159045 · DOI 10.3390/cancers14030778
  5. A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
    Davoodi-Moghaddam Z, Jafari-Raddani F, Noori M, Bashash D. · · 2023 · cited 15× · PMID 36773442 · DOI 10.1016/j.tranon.2023.101636
  6. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.
    Bennani-Baiti N, Ansell S, Feldman AL. · · 2016 · cited 15× · PMID 26581318 · DOI 10.1586/17474086.2016.1122514
  7. Checkpoint inhibition in hematologic malignancies.
    Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172
  8. Treatment Advances in EBV Related Lymphoproliferative Diseases.
    Lv K, Yin T, Yu M, Chen Z, et al · · 2022 · cited 14× · PMID 35515118 · DOI 10.3389/fonc.2022.838817

Verify or expand the search:

Other trials of Brentuximab Vedotin

Trials testing the same drug.

Other recruiting trials for Recurrent Hodgkin Lymphoma

Currently open trials in the same condition.

Other University of Washington trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01703949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing